---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-106156"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-09-09T13:00:19+00:00"
generated_at: "2026-09-09T13:01:05.606161+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports preclinical DA-1726 tissue distribution: highest in adipose, prolonged retention

## Summary
- Preclinical study shows DA-1726-derived radioactivity highest in adipose tissue, with broad distribution and prolonged retention through 144h.
- Tissue-to-plasma ratios increased over time; greatest exposure in abdominal, subcutaneous, brown fat, and liver; minimal CNS penetration.
- CEO cites Phase 1 data: 48 mg dose achieved mean 9.8 cm waist circumference reduction after 8 weeks (Day 54).
- Company expects 16-week topline data in Q4 2026 and 24-week topline results in Q1 2027.

## SEC filing metadata
- accession: 0001104659-26-106156
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-09-09T13:00:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/0001104659-26-106156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/mtva-20260909x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-106156
- JSON: https://secwatch.observer/filing/0001104659-26-106156.json
- Plain text: https://secwatch.observer/filing/0001104659-26-106156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.